WO2001072323A3 - Use of insulin for the treatment of cartilagenous disorders - Google Patents
Use of insulin for the treatment of cartilagenous disorders Download PDFInfo
- Publication number
- WO2001072323A3 WO2001072323A3 PCT/US2001/009230 US0109230W WO0172323A3 WO 2001072323 A3 WO2001072323 A3 WO 2001072323A3 US 0109230 W US0109230 W US 0109230W WO 0172323 A3 WO0172323 A3 WO 0172323A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- treatment
- administration
- cartilage
- injury
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01922571A EP1265630B1 (en) | 2000-03-24 | 2001-03-22 | Use of insulin for the treatment of cartilagenous disorders |
AU4935701A AU4935701A (en) | 2000-03-24 | 2001-03-22 | Use of insulin for the treatment of cartilagenous disorders |
DE60120372T DE60120372T2 (en) | 2000-03-24 | 2001-03-22 | USE OF INSULIN FOR THE TREATMENT OF CORTICAL DISEASES |
CA2402191A CA2402191C (en) | 2000-03-24 | 2001-03-22 | Use of insulin for the treatment of cartilagenous disorders |
JP2001570284A JP2003528149A (en) | 2000-03-24 | 2001-03-22 | Use of insulin for the treatment of cartilage disorders |
IL151408A IL151408A (en) | 2000-03-24 | 2002-08-21 | Use of insulin for the preparation of medicaments for the treatment of cartilagenous disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19210300P | 2000-03-24 | 2000-03-24 | |
US60/192,103 | 2000-03-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001072323A2 WO2001072323A2 (en) | 2001-10-04 |
WO2001072323A3 true WO2001072323A3 (en) | 2002-06-06 |
Family
ID=22708258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/009230 WO2001072323A2 (en) | 2000-03-24 | 2001-03-22 | Use of insulin for the treatment of cartilagenous disorders |
Country Status (11)
Country | Link |
---|---|
US (4) | US6689747B2 (en) |
EP (1) | EP1265630B1 (en) |
JP (2) | JP2003528149A (en) |
AT (1) | ATE328605T1 (en) |
AU (1) | AU4935701A (en) |
CA (1) | CA2402191C (en) |
DE (1) | DE60120372T2 (en) |
DK (1) | DK1265630T3 (en) |
ES (1) | ES2266187T3 (en) |
IL (1) | IL151408A (en) |
WO (1) | WO2001072323A2 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7019192B2 (en) * | 1998-02-27 | 2006-03-28 | Musculoskeletal Transplant Foundation | Composition for filling bone defects |
US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
DE60120372T2 (en) * | 2000-03-24 | 2007-07-05 | Genentech Inc., San Francisco | USE OF INSULIN FOR THE TREATMENT OF CORTICAL DISEASES |
US7090865B2 (en) * | 2001-11-29 | 2006-08-15 | National Jewish Medical And Research Center | Composition and method for treating autoimmune hemolytic anemia |
US20040005999A1 (en) * | 2002-03-07 | 2004-01-08 | Andreasen Kasper Huus | Polyamino acid-based particle insulin preparation |
US20060204544A1 (en) * | 2002-05-20 | 2006-09-14 | Musculoskeletal Transplant Foundation | Allograft bone composition having a gelatin binder |
US20040138116A1 (en) * | 2002-08-30 | 2004-07-15 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
US20070122487A1 (en) * | 2003-03-19 | 2007-05-31 | University Of Kentucky Research Foundation | (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres |
ES2737835T3 (en) * | 2003-04-23 | 2020-01-16 | Valeritas Inc | Hydraulically driven pump for long-term medication administration |
US20050222687A1 (en) * | 2004-04-02 | 2005-10-06 | Gordana Vunjak-Novakovic | Cartilage implant assembly and method for implantation |
US20050064042A1 (en) * | 2003-04-29 | 2005-03-24 | Musculoskeletal Transplant Foundation | Cartilage implant plug with fibrin glue and method for implantation |
US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US20090291112A1 (en) * | 2003-05-16 | 2009-11-26 | Truncale Katherine G | Allograft osteochondral plug combined with cartilage particle mixture |
US20040228897A1 (en) * | 2003-05-16 | 2004-11-18 | Zhang Ping Ye | Methods and apparatus for in vivo cell localization |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US7488348B2 (en) * | 2003-05-16 | 2009-02-10 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
WO2005066215A1 (en) * | 2003-12-30 | 2005-07-21 | Genzyme Corporation | Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use |
GB0402129D0 (en) * | 2004-01-30 | 2004-03-03 | King S College London | Therapeutic and diagnostic peptides |
US9089636B2 (en) * | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
US8512730B2 (en) * | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
CA2570521C (en) * | 2004-07-12 | 2013-06-25 | Isto Technologies, Inc. | Tissue matrix system |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US20080220044A1 (en) * | 2007-03-06 | 2008-09-11 | Semler Eric J | Cancellous construct with support ring for repair of osteochondral defects |
US20090149893A1 (en) * | 2007-12-05 | 2009-06-11 | Semler Eric J | Cancellous Bone Implant for Cartilage Repair |
US20090155229A1 (en) * | 2004-12-06 | 2009-06-18 | Avner Yayon | Chondrocyte-based implant for the delivery of therapeutic agents |
US7815926B2 (en) * | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
CA2623106C (en) | 2005-09-19 | 2013-12-24 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
CA2631520A1 (en) | 2005-12-07 | 2007-06-14 | Isto Technologies, Inc. | Cartilage repair methods |
US20070141160A1 (en) * | 2005-12-15 | 2007-06-21 | Brown Laura J | Method of treatment for osteoarthritis by local intra-articular injection of microparticles |
SG173319A1 (en) | 2006-03-30 | 2011-08-29 | Valeritas Inc | Multi-cartridge fluid delivery device |
DK2148691T3 (en) * | 2007-02-05 | 2015-08-17 | Apellis Pharmaceuticals Inc | Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system |
US8435551B2 (en) * | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
JP5302952B2 (en) * | 2007-04-19 | 2013-10-02 | ドン・ア・ファーム・カンパニー・リミテッド | Biodegradable microsphere composition suitable for controlled release of glycoregulatory peptide and method for producing the same |
EP2147311A4 (en) * | 2007-04-26 | 2010-08-11 | Genera Istrazivanja D O O | Blood biomarkers for bone fracture and cartilage injury |
US8685107B2 (en) | 2007-07-03 | 2014-04-01 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
US20090054984A1 (en) | 2007-08-20 | 2009-02-26 | Histogenics Corporation | Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects |
WO2009111069A1 (en) * | 2008-03-05 | 2009-09-11 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US8691759B2 (en) | 2008-03-18 | 2014-04-08 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
CN104628855A (en) * | 2008-05-05 | 2015-05-20 | 诺维莫尼公司 | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof |
US9289302B2 (en) * | 2008-07-28 | 2016-03-22 | Zimmer, Inc. | Mosaicplasty constructs |
US8263069B2 (en) * | 2008-12-31 | 2012-09-11 | Johnson Lanny L | Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions |
AU2010244142B2 (en) * | 2009-05-05 | 2016-07-21 | Novimmune Sa | Anti-IL-17F antibodies and methods of use thereof |
US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
US8722615B2 (en) * | 2009-12-02 | 2014-05-13 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
JP2013535467A (en) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | Recombinantly expressed insulin polypeptide and uses thereof |
US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
AR087433A1 (en) * | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | N-GLICOSILATED INSULIN ANALOGS |
WO2013110069A1 (en) * | 2012-01-20 | 2013-07-25 | Case Western Reserve University | Glutamic acid-stabilized insulin analogues |
US10245306B2 (en) | 2012-11-16 | 2019-04-02 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
US9968623B2 (en) | 2013-08-29 | 2018-05-15 | Lanny Leo Johnson | Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent |
US10457716B2 (en) * | 2014-08-06 | 2019-10-29 | University Of Notre Dame Du Lac | Protein folding and methods of using same |
US10179191B2 (en) | 2014-10-09 | 2019-01-15 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
US11925656B2 (en) * | 2014-11-05 | 2024-03-12 | Lanny Leo Johnson | Biological total joint replacement |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
CN110087674B (en) | 2016-12-16 | 2023-01-03 | 诺和诺德股份有限公司 | Pharmaceutical composition containing insulin |
JP2021520247A (en) | 2018-04-03 | 2021-08-19 | コンバージェント デンタル, インコーポレイテッド | Laser system for surgical applications |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051262A2 (en) * | 1998-04-03 | 1999-10-14 | Chiron Corporation | Use of igfi for treating articular cartilage disorders |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US544047A (en) * | 1895-08-06 | Rheostat | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4430266A (en) | 1980-11-28 | 1984-02-07 | Eli Lilly And Company | Process for producing an insulin precursor |
NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
FI78616C (en) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Process for preparing an infused stabilized insulin solution having an elevated zinc content |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
DK58285D0 (en) | 1984-05-30 | 1985-02-08 | Novo Industri As | PEPTIDES AND MANUFACTURING AND USING THEREOF |
US4569791A (en) | 1984-06-14 | 1986-02-11 | Eli Lilly And Company | Anti-diabetic compounds |
US4569792A (en) | 1984-06-14 | 1986-02-11 | Eli Lilly And Company | Anti-diabetic compounds |
US4581165A (en) | 1984-06-14 | 1986-04-08 | Eli Lilly And Company | Anti-diabetic compounds |
EP0192743A4 (en) | 1984-08-31 | 1988-05-10 | Genetics Inst | Modified insulin precursors products and processes. |
DK129385A (en) | 1985-03-22 | 1986-09-23 | Novo Industri As | PEPTIDES AND PREPARATION THEREOF |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
IT1198449B (en) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | ESTERS OF POLYVALENT ALCOHOLS OF HYALURONIC ACID |
CA1340772C (en) | 1987-12-30 | 1999-09-28 | Patricia Tekamp-Olson | Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences |
DK257988D0 (en) | 1988-05-11 | 1988-05-11 | Novo Industri As | NEW PEPTIDES |
DE3837825A1 (en) | 1988-11-08 | 1990-05-10 | Hoechst Ag | NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM |
JPH04502465A (en) | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | human insulin analogue |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
SE500903C2 (en) | 1989-12-20 | 1994-09-26 | Atlas Copco Constr & Mining | Rock drilling rig |
NZ236618A (en) | 1990-01-03 | 1997-06-24 | Ciba Geigy Ag | Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound |
US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
IL102240A0 (en) | 1991-06-21 | 1993-01-14 | Lilly Co Eli | Insulin analogs |
US5378613A (en) | 1991-09-24 | 1995-01-03 | Eli Lilly And Company | Method for increased expression of low molecular weight recombinant polypeptides |
NZ245170A (en) | 1991-11-26 | 1994-07-26 | Lilly Co Eli | Insulin and proinsulin analogues with arg at b31, b32 and ao and pharmaceutical compositions |
GB9204155D0 (en) | 1992-02-27 | 1992-04-08 | Amp Gmbh | Improved latching mechanism for blindmate electrical connectors |
TW267102B (en) | 1992-03-13 | 1996-01-01 | Ciba Geigy | |
DE4208552A1 (en) * | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | TOPICAL MEDICINE FORMS WITH INSULIN |
NZ255461A (en) | 1992-08-20 | 1996-12-20 | Biotechnology & Biolog Science | Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity |
WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
US5506302A (en) | 1993-09-10 | 1996-04-09 | Shin-Etsu Chemical Co., Inc. | Organopolysiloxane composition and rubber substrate having a coating thereof |
CZ287945B6 (en) | 1993-09-17 | 2001-03-14 | Novo Nordisk A/S | Insulin derivative and pharmaceutical preparation in which it is comprised and which is intended for treating diabetes mellitus |
BR9400600A (en) | 1994-02-17 | 1995-10-24 | Finep Financiadora De Estudos | Processes for the production of a recombinant protein and / or glycosylphosphatidylinositol (GPI) in cells of eukaryotic microorganisms and to obtain S. cerevisae yeasts; yeast cell nucleotide sequence; culture medium; medicine or vaccine; and product of said processes |
US5597700A (en) | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
US5444047A (en) | 1994-06-16 | 1995-08-22 | Dipasquale; Gene | Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I |
US5559094A (en) | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
HRP940432B1 (en) | 1994-08-05 | 2003-10-31 | Pliva Pharm & Chem Works | Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin |
CN1157562A (en) | 1994-09-09 | 1997-08-20 | 武田药品工业株式会社 | Sustained release preparation containing metal salt of peptide |
CZ290079B6 (en) | 1994-12-29 | 2002-05-15 | Bio-Technology General Corp. | Process for preparing insulin and intermediate for this process |
US5686113A (en) * | 1995-03-21 | 1997-11-11 | Temple University Of The Commonwealth System Of Higher Education | Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses |
BR9608542A (en) | 1995-06-07 | 1999-11-30 | Alkermes Inc | Composition for the sustained release of human growth hormone |
ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
DE69717263T2 (en) | 1996-03-28 | 2003-07-24 | Takeda Chemical Industries Ltd | PREPARATION WITH DELAYED RELEASE AND THEIR PRODUCTION |
WO1997039032A1 (en) | 1996-04-17 | 1997-10-23 | Neurocrine Biosciences, Inc. | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6004573A (en) * | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
CA2369451C (en) * | 1999-04-08 | 2009-09-22 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
DE60120372T2 (en) * | 2000-03-24 | 2007-07-05 | Genentech Inc., San Francisco | USE OF INSULIN FOR THE TREATMENT OF CORTICAL DISEASES |
-
2001
- 2001-03-22 DE DE60120372T patent/DE60120372T2/en not_active Expired - Lifetime
- 2001-03-22 EP EP01922571A patent/EP1265630B1/en not_active Expired - Lifetime
- 2001-03-22 CA CA2402191A patent/CA2402191C/en not_active Expired - Fee Related
- 2001-03-22 JP JP2001570284A patent/JP2003528149A/en not_active Withdrawn
- 2001-03-22 AU AU4935701A patent/AU4935701A/en active Pending
- 2001-03-22 US US09/815,229 patent/US6689747B2/en not_active Expired - Lifetime
- 2001-03-22 DK DK01922571T patent/DK1265630T3/en active
- 2001-03-22 WO PCT/US2001/009230 patent/WO2001072323A2/en active IP Right Grant
- 2001-03-22 AT AT01922571T patent/ATE328605T1/en active
- 2001-03-22 ES ES01922571T patent/ES2266187T3/en not_active Expired - Lifetime
-
2002
- 2002-08-21 IL IL151408A patent/IL151408A/en not_active IP Right Cessation
-
2003
- 2003-12-17 US US10/740,098 patent/US7268112B2/en not_active Expired - Fee Related
-
2006
- 2006-10-04 US US11/538,700 patent/US20070049516A1/en not_active Abandoned
-
2010
- 2010-06-28 US US12/825,208 patent/US20100266698A1/en not_active Abandoned
-
2012
- 2012-01-27 JP JP2012015753A patent/JP2012121896A/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051262A2 (en) * | 1998-04-03 | 1999-10-14 | Chiron Corporation | Use of igfi for treating articular cartilage disorders |
Non-Patent Citations (2)
Title |
---|
G. MAOR ET AL.: "Insulin enhances the growth of cartilage in organ and tissue cultures of mouse neonatal mandibular condyle.", CALCIFIED TISSUE INTERNATIONAL, vol. 52, no. 4, 1993, Berlin, DE, pages 291 - 299, XP001064269 * |
G.E. UMPIERREZ ET AL.: "Correction of altered collagen metabolism in diabetic animals with insulin therapy.", MATRIX, vol. 9, no. 4, 1989, Stuttgart, DE, pages 336 - 342, XP001064200 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001072323A2 (en) | 2001-10-04 |
ES2266187T3 (en) | 2007-03-01 |
ATE328605T1 (en) | 2006-06-15 |
EP1265630A2 (en) | 2002-12-18 |
DE60120372T2 (en) | 2007-07-05 |
DK1265630T3 (en) | 2006-10-09 |
US20100266698A1 (en) | 2010-10-21 |
US6689747B2 (en) | 2004-02-10 |
US20070049516A1 (en) | 2007-03-01 |
IL151408A0 (en) | 2003-04-10 |
US20040138101A1 (en) | 2004-07-15 |
DE60120372D1 (en) | 2006-07-20 |
US20020058614A1 (en) | 2002-05-16 |
IL151408A (en) | 2009-08-03 |
CA2402191A1 (en) | 2001-10-04 |
CA2402191C (en) | 2012-03-13 |
EP1265630B1 (en) | 2006-06-07 |
JP2012121896A (en) | 2012-06-28 |
US7268112B2 (en) | 2007-09-11 |
AU4935701A (en) | 2001-10-08 |
JP2003528149A (en) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001072323A3 (en) | Use of insulin for the treatment of cartilagenous disorders | |
IL200484A0 (en) | Use of wisp polypeptides wisp for the preparation of medicaments | |
ATE380109T1 (en) | SYSTEMS, METHODS AND DEVICES FOR PRODUCING DOSAGE FORMS | |
ZA977783B (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
WO2004000354A3 (en) | Method of treating the syndrome of lipodystrophy | |
EA200300503A1 (en) | NEW MEDICINAL COMPOSITIONS BASED ON SALTS OF TIOTROPY AND SALTS OF SALMETEROL | |
WO2004091540A3 (en) | Methods of treating pain and compositions for use therefor | |
WO2001043732A3 (en) | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies | |
WO2002070524A3 (en) | N-but-3-enyl norbuprenorphine and its use as analgesic | |
EA200400734A1 (en) | METHOD AND COMPOSITION FOR POTENTIATING OPIATIVE ANALGETIC ACTION | |
EP1262196A3 (en) | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | |
WO2002007678A3 (en) | Mu-conopeptides | |
WO2002096420A3 (en) | Method for treating nerve injury caused by surgery | |
DE60140960D1 (en) | USE OF SERP-1 IN COMBINATION WITH AN IMMUNOSUP PRESSOR FOR THE TREATMENT OF ARTHRITIS | |
HU9700661D0 (en) | Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
MY133169A (en) | Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect | |
AU4937499A (en) | Use of succinic acid or salts thereof and method of treating insulin resistance | |
EP1270000A3 (en) | Benzoic acid substituted benzopyrans for the treatment of atherosclerosis | |
WO2000051585A3 (en) | Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume | |
BR0316123A (en) | Aqueous pharmaceutical formulation, use of an aqueous pharmaceutical formulation, and method of treating a patient in need of antithrombotic treatment | |
WO1995005364A3 (en) | Inhibitors of biogenic amine transporters | |
YU59102A (en) | COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF A DISEASE MEDIATED BY THE ALPHA-2β-ADRENOCEPTOR | |
MEP20308A (en) | THE USE OF R(+)-alpha-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001249357 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151408 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001922571 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2402191 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 570284 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2001922571 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001922571 Country of ref document: EP |